Citi Boosts Eli Lilly with Buy Rating, Eyes Growth
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
- Latest
- Trending
Citi resumes Eli Lilly coverage with Buy rating, driven by optimistic tirzepatide forecasts for diabetes and obesity treatments.
Janet Rathod, with decades in cybersecurity, joins Johns Hopkins as CISO, enhancing security in education and health sectors.
Investors can navigate Wells Fargo's stock amidst recent regulatory challenges with strategic insights for potential growth.
MicroStrategy buys 18,300 BTC for $1.1B, solidifying its position as the largest corporate Bitcoin holder.
A security flaw in Apple's Vision Pro headset could infer data from gaze typing. It's patched in visionOS 1.3.
U.S. plans to curb low-value Chinese imports, affecting e-commerce giants like JD.com, Alibaba, and Pinduoduo.
New US tariffs on Chinese imports, including EVs, solar cells, and semiconductors, aim to shift supply chains from China.
WebPT and Intel partner on AI motion capture for physical therapy, integrating RealSense technology into EMR for enhanced patient care.
Discover five leading Bitcoin-centric stocks poised for growth as crypto markets anticipate a rebound.
The Virtual Reality market is set for rapid growth, expected to reach USD 143.86 billion by 2029, thanks to advancements ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.